Annemiek Walenkamp

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Glioma progression is shaped by genetic evolution and microenvironment interactions

Frederick S. Varn, Kevin C. Johnson, Jason T. Huse et al. · Cell · 2022 · 498 citations · Full text

Medicine, Cancer Biology, Oncology +16

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis

Myra E. van Linde, Cyrillo G. Brahm, Philip C. De Witt Hamer et al. · Journal of Neuro-Oncology · 2017 · 201 citations · Full text

Medicine, Neurosurgery, Oncology +16

CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy

Urszula Domańska, Hetty Timmer‐Bosscha, Wouter B. Nagengast et al. · Neoplasia · 2012 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2019 · 189 citations · Full text

Medicine, Oncology, Pharmacology +17